Sign In
Free Newsletter
Amneal closes $1.1B Kashiv Biosciences acquisition
The combination of Bridgewater-based Amneal Pharmaceuticals and Kashiv Biosciences from Piscataway creates a global leader in biosimilars ahead of a looming Loss of Exclusivity set to hit the market.
AstraZeneca, BMS not pursuing merger talks: Reuters
Reuters says AstraZeneca and Bristol Myers Squibb are not pursuing merger talks, despite earlier reports of a potential $400 billion deal.
IVI RMA to debut automated IVF system AURA in US clinic
IVI RMA and Conceivable Life Sciences will debut the AURA robotic IVF system in a U.S. clinic, advancing automation-assisted fertility care while expanding access and consistency in care.
Report: NJ expands life sciences leadership
New Jersey expands its life sciences leadership with biotech growth, new biomanufacturing space and innovation investments.
J&J secures HELIX innovation hub naming rights
Johnson & Johnson secured naming rights at the HELIX innovation hub in New Brunswick, supporting New Jersey biotech startups.
BioMarin cuts 58 jobs at Amicus HQ in Princeton
The layoffs at Amicus Therapeutics’ Princeton headquarters follow BioMarin's recent $4.8 billion acquisition of the biotech.
Bristol Myers Squibb inks $15.2B drug deal with Hengrui
The partnership with Hengrui Pharma will develop 13 oncology, hematology and immunology drug programs worldwide.
Bristol Myers Squibb launches ‘Won’t Lose’ World Cup campaign
The marketing push tied to the global event arriving this summer in N.J. and the U.S. more broadly highlights drug development, resilience and breakthrough medicines.
Novartis reports progress on $23B US manufacturing expansion
Novartis advances its $23B U.S. manufacturing plan, expanding R&D and drug production as it aims to produce key medicines domestically.
Cellares to manufacture Cabaletta CAR-T under 10-year deal
The 10-year deal will enable automated, large-scale production for autoimmune diseases with Cabaletta Bio's rese-cel therapy.
FDA approves J&J’s Caplyta to prevent schizophrenia relapse
The FDA approved Johnson & Johnson’s Caplyta to prevent schizophrenia relapse, expanding its use after trial data showed reduced risk.
Merck wins FDA approval for once-daily HIV pill Idvynso
The clearance for Idvynso, which combines doravirine and islatravir for adults with HIV-1, helps expand treatment options for patients.
